Open access · OA
via Europe PMC
Restorin<sup>®</sup> NR is a Highly Efficient NAD<sup>+</sup> Precursor.
Weiss B, Cao R, Liu Y, Chen J, Marshall GL.
Drug design, development and therapy · 2026
Abstract
<h4>Introduction</h4>Nicotinamide adenine dinucleotide (NAD+) is vital for maintaining normal cellular function. Aging-associated NAD+ decline is linked to the onset and progression of age-related diseases. Consequently, oral supplementation of NAD+ precursors has been shown to improve disease-relevant phenotypes and physiological outcomes in model organisms. Among NAD+ precursors, nicotinamide riboside (NR) has attracted interest owing to its potent in vivo NAD+ biosynthetic activity. However, NR exhibits poor stability in the circulatory system. Thus, there is considerable interest in discovering effective NAD+ precursor forms that can address these limitations. Here, we report Restorin NR, a proprietary crystalline form of NR fumarate, as a novel NAD+ enhancer.<h4>Methods</h4>The current study was performed to compare the effectiveness of three different NAD+ precursors, including nicotinamide mononucleotide (NMN), NR chloride, and Restorin NR in boosting NAD+ levels in an aged murine model.<h4>Results</h4>The results showed that Restorin NR significantly increased NAD+ levels above equivalent doses of NMN or NR chloride. Notably, Restorin NR at the low dose of 0.33 mmol/kg/day induced blood NAD+ elevation statistically equivalent to that of a higher dose of NR chloride or NMN (1 mmol/kg/day, n=11). At the matched dose of 1 mmol/kg/day, Restorin NR yielded significantly higher circulating NAD+ levels than either comparison treatment. These results confirm Restorin NR's superiority to the tested precursors for NAD+ concentrations in circulation.<h4>Discussion</h4>Overall, our research identifies a new crystalline salt form of NR and classifies Restorin NR as a promising new therapeutic agent to enhance NAD+ levels and combat aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.2147/dddt.s639156
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
B, W., R, C., Y, L., J, C., & GL., M. (2026). Restorin<sup>®</sup> NR is a Highly Efficient NAD<sup>+</sup> Precursor. <em>Drug design, development and therapy</em>. https://doi.org/10.2147/dddt.s639156
Vancouver
B W, R C, Y L, J C, GL. M. Restorin<sup>®</sup> NR is a Highly Efficient NAD<sup>+</sup> Precursor. Drug design, development and therapy. 2026. doi:10.2147/dddt.s639156.
BibTeX
@article{weiss2026Restor,
title = {Restorin<sup>®</sup> NR is a Highly Efficient NAD<sup>+</sup> Precursor.},
author = {Weiss B and Cao R and Liu Y and Chen J and Marshall GL.},
journal = {Drug design, development and therapy},
year = {2026},
doi = {10.2147/dddt.s639156},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Drug Design Development and Therapy 2026
Open access · CC-BY
Restorin® NR is a Highly Efficient NAD+ Precursor
DOAJ (DOAJ: Directory of Open Access Journals) 2026
Preprint · CC-BY
Restorin® NR is a Highly Efficient NAD+ Precursor
Scientific Reports 2022
Open access · CC-BY
Porcine placental extract increase the cellular NAD levels in human epidermal keratinocytes
Annals of Clinical and Medical Case Reports 2025
Open access · OA
Intervention Study Comparing Blood NAD+ Concentrations with Liposomal and Non-Liposomal Nicotinamide Mononucleotide
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
Oral supplementation with Nicotinamide Riboside treatment protects RGCs in DBA/2J mouse model
Antioxidants 2024
Open access · CC-BY